Navigation Links

Biology Technology

Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection

5/4/2015
NEW YORK , May 4, 2015 Many of us take a healthy immune system for granted. But for certain infants with rare, inherited mutations of certain genes, severe infection and death are stark consequences of their impaired immune responses. Now, researchers at NYU Langone Medical Center have identified an important role for calcium signaling in immune responses to chron... [Comments]

Tobira Therapeutics Completes Financing and Merger with Regado Biosciences

5/4/2015
SOUTH SAN FRANCISCO, Calif. , May 4, 2015 Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and immuno-inflammatory diseases, announced today the completion of its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, through May 4). In conjunction with the closing o... [Comments]

JSS Medical Canada widens its global presence across Asia/Pacific region

5/4/2015
MONTREAL , May 4, 2015 /PRNewswire/ - JSS Medical Research Inc., a Montreal based Contract Research Organization (CRO), announced today that it concluded the acquisition of Max Neeman International (MNI), with head office in New Delhi, India . Additional regional offices are located in Ahmedabad, Bangalore , Chennai and Mumbai . Through a US subsidiary, a regional office is l... [Comments]

Scientists dramatically improve method for finding common genetic alterations in tumors

5/4/2015
MEMPHIS, Tenn. , May 4, 2015   St. Jude Children's Research Hospital scientists have developed a significantly better computer tool for finding genetic alterations that play an important role in many cancers but were difficult to identify with whole-genome sequencing. The findings appear today in the scientific journal Nature Methods . The tool is an algorit... [Comments]

GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients

5/4/2015
BOSTON , May 4, 2015 GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced that it has initiated dosing of Alzheimer's patients in a Phase 1b clinical trial of its lead product candidate, GC021109, a compound developed as a potential disease-mod... [Comments]

Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014

5/4/2015
TEL AVIV, Israel , May 4, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2014 with the U.S. Securities and Exchange Commission ("SEC"). The annual report on Form 20-F contains information regarding its biotechnology project for the development of antibodies in the area of... [Comments]

Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets

5/4/2015
STONY BROOK, N.Y. , May 4, 2015  Traverse Biosciences announced today that it has executed a $250,000 cooperative research and development agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: PETX ) to advance the development of TRB-N0224 for the treatment and control of periodontal disease in companion animals, including dogs and cats.  Traverse Biosciences has... [Comments]

Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline

5/4/2015
TORONTO , May 4, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, is pleased to announce the appointment of Dr. Roger J Garceau, to its Board of Directors. With extensive experience guiding biotech companies in matters including corporate development and clinical strategy, his appointment strengthens Fluorinov's leadership team and adds significant regulatory exper... [Comments]

Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies

5/4/2015
TORONTO , May 4, 2015 /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) and its partners are pleased to announce the formation of Turnstone Biologics Inc. (Turnstone), a biotechnology company focussed on developing treatments for cancer that harness the patient's own immune system. The company represents a unique collaboration between the Children's Hospital of Eastern Onta... [Comments]

Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing

5/4/2015
ROCKVILLE, Md. , May 4, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that an independent team of researchers from South Korea have reported that Thymosin B4 (TB4) plays an important role in accelerating the repair of second-degree dermal burn wounds, induced in an experimental mouse model, by promoting blood vessel... [Comments]

Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances

5/4/2015
Boston, MA (PRWEB) May 04, 2015 Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Biologics™ 5.0 , the latest version of its enterprise solution for biologics R&D. This first-in-class workflow platform for biopharma R&D enables more efficient discovery and development of novel biotherape... [Comments]

Medicine Technology

DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award

5/4/2015
BOSTON , May 4, 2015  In an effort to raise awareness and the need for collective action to improve oral health nationwide, DentaQuest established the Health Equity Hero Awards to celebrate the efforts of local leaders championing the cause. More than 83 million people in the United States face barriers to dental care. These barriers are most significant for those wh... [Comments]

Luminex Corporation Reports First Quarter 2015 Results

5/4/2015
AUSTIN, Texas, May 4, 2015 Luminex Corporation (NASDAQ: LMNX ) today announced financial results for the first quarter ended March 31, 2015. Financial and operating highlights include the following: Consolidated first quarter revenue of $57.7 million, a 2 percent increase over the first quarter of 2014. First quarter assay revenue of $25.4 million, a 17 percent increase o... [Comments]

Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Second Quarter 2015 Results And Conference Call

5/4/2015
GLENWOOD, Ill. , May 4, 2015  Landauer, Inc. (NYSE: LDR ), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today announced it will release financial results for the fiscal second quarter 2015 after the market close on Monday, May 11, 2015. The Co... [Comments]

Xencor Reports First Quarter 2015 Financial and Operating Results

5/4/2015
MONROVIA, Calif., May 4, 2015  Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the first quarter ended March 31, 2015 and provided a review of business highlights. "Following our e... [Comments]

OncoGenex to Report First Quarter 2015 Financial Results on May 14, 2015

5/4/2015
BOTHELL, Wash. and VANCOUVER, British Columbia , May 4, 2014  OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that it will report its first quarter 2015 financial results on Thursday, May 14, 2015. Company management will host a conference call and live webcast at 4:30 p.m. Eastern Time to provide an overview of financial results, clinical development... [Comments]

Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs

5/4/2015
SAN DIEGO , May 4, 2015  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced that Dr. Bill Aurora has joined the company as Vice President, Medical Affairs. "We are very pleased to welcome Dr. Bill Aurora to the Neurocrine team as our Vice President, Medical Affairs," said Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences. "Bi... [Comments]

BioSpecifics Technologies Corp. to Report First Quarter 2015 Financial Results on Monday, May 11, 2015

5/4/2015
LYNBROOK, N.Y. , May 4, 2015  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX ® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX ®  in the EU, will announce its first quarter 2015 financial results after the close of the U.S. financial... [Comments]

AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results

5/4/2015
REDWOOD CITY, Calif. , May 4, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided a regulatory update on Zalviso and reported financial results for the three months ended March 31, 2015. Zalviso Regu... [Comments]

PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update

5/4/2015
SOUTH PLAINFIELD, N.J. , May 4, 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced a corporate update and reported financial results for the first quarter ending March 31, 2015. "We are off to a strong start this year. In our first full quarter since the commercial launch, we have seen strong support for access to Translarna, the first treatment for nonsense mutat... [Comments]

Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference

5/4/2015
THOUSAND OAKS, Calif. , May 4, 2015  Amgen (NASDAQ: AMGN ) will present at the Deutsche Bank 40th Annual Healthcare Conference at 8 a.m. ET on Thursday, May 7, 2015, at the InterContinental in Boston . Anthony C. Hooper , executive vice president of Global Commercial Operations at Amgen, will present at the conference. Live audio of the presentation can be accessed fr... [Comments]

Microbrush International Announces Acquisition of DentiSmart

5/4/2015
GRAFTON, Wis. , May 4, 2015 Microbrush International, a leading developer, producer and marketer of high-quality consumables used in dental restorative procedures, today announced the acquisition of DentiSmart LLC. DentiSmart is a producer of an innovative sectional matrix system used in dental restorative procedures. "We are excited about the opportunity to add DentiSmart t... [Comments]

(Date:5/4/2015)... ROCKVILLE, Md. , May 4, 2015 /PRNewswire/ ... "RegeneRx") today announced that an independent team of ... have reported that Thymosin B4 (TB4) plays an ... dermal burn wounds, induced in an experimental mouse ... rapid vascular remodeling of damaged dermal tissue.  The ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: ... developing products that address unmet medical needs in the ... it will be presenting preclinical data from three of ... Defense Science and Technology Conference on May 12-14, 2015 ... at 701 Convention Plaza, St. Louis MO ...
(Date:5/4/2015)... May 4, 2015   Tocagen Inc. , ... data from Tocagen,s ongoing investigational studies were presented ... the American Association of Neurological Surgeons (AANS)/Congress of ... 1-2, 2015, in Washington, D.C. ... a meeting with FDA and continues to advance ...
(Date:5/4/2015)... Marianjoy Rehabilitation Hospital ... and hand impairments by acquiring the Armeo®Spring arm ... network site. , Secured through grant support of ... treatment option for patients with upper extremity weakness ... one of just four Illinois providers offering treatment ...
Breaking Biology Technology:Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2
... Genoptix, Inc.,(Nasdaq: GXDX ), a specialized laboratory services ... Life Sciences Conference,scheduled to take place at the Grand ... 2008., Douglas Schuling, Senior Vice President and CFO ... 22, beginning at,approximately 3:30 pm EDT. Mr. Schuling will ...
... of oil palm plantations will worsen the dual environmental ... are better protected, warn scientists in the most comprehensive ... Emily Fitzherbert from the Zoological Society of London and ... debate over the role of palm oil production in ...
... will likely be the move from today,s two-dimensional chips ... is now running at 1.4 gigahertz at the University ... Rochester chip is not simply a number of regular ... designed and built specifically to optimize all key processing ...
Cached Biology Technology:Genoptix Announces Participation at the UBS Global Life Sciences Conference 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 3First 3-D processor runs at 1.4 Ghz on new architecture 2
(Date:5/4/2015)... 4, 2015 DePuy Synthes CMF* today announced ... first commercially available biosynthesized dural replacement derived from cellulose ... part of the DePuy Synthes Companies of Johnson & ... that covers and protects the brain and spinal cord. ... surgeons to access the brain. A dural graft, which ...
(Date:5/4/2015)... , May 4, 2015 Former NASA ... News online last week where he discussed Theradome™, the ... be FDA-cleared. The FOX segment shows firsthand how, via ... affordable hair loss solution that will not require surgery ... the mitochondria at the base of the hair follicle, ...
(Date:5/4/2015)... and TORONTO , May 4, ... (OTCQB:GNBT) today announced that it intends to dividend to ... upon completion of a definitive licensing agreement to license ... ( www.smoofi.com ) (OTCQB:SMFI). As announced on ... of intent in respect of the licensing of its ...
Breaking Medicine Technology:DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5